|
1
|
Saracci R and Wild CP: Fifty years of the
international agency for research on cancer (1965 to 2015). Int J
Cancer. 138:1309–1311. 2016. View Article : Google Scholar
|
|
2
|
Chen J, Odenike O and Rowley JD:
Leukaemogenesis: More than mutant genes. Nat Rev Cancer. 10:23–36.
2010. View Article : Google Scholar :
|
|
3
|
Miranda-Filho A, Pineros M, Ferlay J,
Soerjomataram I, Monnereau A and Bray F: Epidemiological patterns
of leukaemia in 184 countries: A population-based study. Lancet
Haematol. 5:e14–e24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cazzola M: Introduction to a review
series: The 2016 revision of the WHO classification of tumors of
hematopoietic and lymphoid tissues. Blood. 127:2361–2364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Landau DA, Tausch E, Taylor-Weiner AN,
Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M,
Böttcher S, et al: Mutations driving CLL and their evolution in
progression and relapse. Nature. 526:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Apperley JF: Chronic myeloid leukaemia.
Lancet. 385:1447–1459. 2015. View Article : Google Scholar
|
|
7
|
Bullinger L, Döhner K and Döhner H:
Genomics of acute myeloid leukemia diagnosis and pathways. J Clin
Oncol. 35:934–946. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malard F and Mohty M: Acute lymphoblastic
leukaemia. Lancet. 395:1146–1162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bosch F and Dalla-Favera R: Chronic
lymphocytic leukaemia: From genetics to treatment. Nat Rev Clin
Oncol. 16:684–701. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Figueroa ME, Lugthart S, Li Y,
Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J,
van Putten W, Skrabanek L, et al: DNA methylation signatures
identify biologically distinct subtypes in acute myeloid leukemia.
Cancer Cell. 17:13–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vu LP, Cheng Y and Kharas MG: The biology
of m6A RNA methylation in normal and malignant
hematopoiesis. Cancer Discov. 9:25–33. 2019. View Article : Google Scholar
|
|
12
|
Sasaki K, Strom SS, O'Brien S, Jabbour E,
Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P,
et al: Relative survival in patients with chronic-phase chronic
myeloid leukaemia in the tyrosine-kinase inhibitor era: Analysis of
patient data from six prospective clinical trials. Lancet Haematol.
2:e186–e193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Porter DL, Hwang WT, Frey NV, Lacey SF,
Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al:
Chimeric antigen receptor T cells persist and induce sustained
remissions in relapsed refractory chronic lymphocytic leukemia. Sci
Transl Med. 7:303ra1392015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Turtle CJ, Hanafi LA, Berger C, Gooley TA,
Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto
TM, et al: CD19 CAR-T cells of defined
CD4+:CD8+ composition in adult B cell ALL
patients. J Clin Invest. 126:2123–2138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schepers K, Campbell TB and Passegue E:
Normal and leukemic stem cell niches: Insights and therapeutic
opportunities. Cell Stem Cell. 16:254–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamashita M, Dellorusso PV, Olson OC and
Passegué E: Dysregulated haematopoietic stem cell behaviour in
myeloid leukaemogenesis. Nat Rev Cancer. 20:365–382. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Coussens LM, Zitvogel L and Palucka AK:
Neutralizing tumor-promoting chronic inflammation: A magic bullet?
Science. 339:286–291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kang I and Bucala R: The immunobiology of
MIF: Function, genetics and prospects for precision medicine. Nat
Rev Rheumatol. 15:427–437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bucala R and Donnelly SC: Macrophage
migration inhibitory factor: A probable link between inflammation
and cancer. Immunity. 26:281–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benjamin D, Aderka D, Livni E, Joshua H,
Shaklai M and Pinkhas J: Migration inhibition factor activity in
sera of patients with chronic lymphatic leukemia. J Natl Cancer
Inst. 63:1175–1177. 1979.PubMed/NCBI
|
|
23
|
Nobre CC, de Araújo JM, Fernandes TA,
Cobucci RN, Lanza DC, Andrade VS and Fernandes JV: Macrophage
migration inhibitory factor (MIF): Biological activities and
relation with cancer. Pathol Oncol Res. 23:235–244. 2017.
View Article : Google Scholar
|
|
24
|
Sun HW, Bernhagen J, Bucala R and Lolis E:
Crystal structure at 2.6-A resolution of human macrophage migration
inhibitory factor. Proc Natl Acad Sci USA. 93:5191–5196. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sparkes A, De Baetselier P, Roelants K, De
Trez C, Magez S, Van Ginderachter JA, Raes G, Bucala R and
Stijlemans B: The non-mammalian MIF superfamily. Immunobiology.
222:473–482. 2017. View Article : Google Scholar :
|
|
26
|
Bloom BR and Bennett B: Mechanism of a
reaction in vitro associated with delayed-type hypersensitivity.
Science. 153:80–82. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pantouris G, Syed MA, Fan C, Rajasekaran
D, Cho TY, Rosenberg EM Jr, Bucala R, Bhandari V and Lolis EJ: An
Analysis of MIF structural features that control functional
activation of CD74. Chem Biol. 22:1197–1205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harris J, VanPatten S, Deen NS, Al-Abed Y
and Morand EF: Rediscovering MIF: New tricks for an old cytokine.
Trends Immunol. 40:447–462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rich AR and Lewis MR: The nature of
allergy in tuberculosis as revealed by tissue culture studies. Bull
Johns Hopkins Hosp. 50:115–131. 1932.
|
|
30
|
David JR: Delayed hypersensitivity in
vitro: Its mediation by cell-free substances formed by lymphoid
cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77. 1966.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bernhagen J, Calandra T, Mitchell RA,
Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A and Bucala R:
MIF is a pituitary-derived cytokine that potentiates lethal
endotoxaemia. Nature. 365:756–759. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Petrovsky N, Socha L, Silva D, Grossman
AB, Metz C and Bucala R: Macrophage migration inhibitory factor
exhibits a pronounced circadian rhythm relevant to its role as a
glucocorticoid counter-regulator. Immunol Cell Biol. 81:137–143.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Calandra T, Bernhagen J, Mitchell RA and
Bucala R: The macrophage is an important and previously
unrecognized source of macrophage migration inhibitory factor. J
Exp Med. 179:1895–1902. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bacher M, Metz CN, Calandra T, Mayer K,
Chesney J, Lohoff M, Gemsa D, Donnelly T and Bucala R: An essential
regulatory role for macrophage migration inhibitory factor in
T-cell activation. Proc Natl Acad Sci USA. 93:7849–7854. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Daryadel A, Grifone RF, Simon HU and
Yousefi S: Apoptotic neutrophils release macrophage migration
inhibitory factor upon stimulation with tumor necrosis
factor-alpha. J Biol Chem. 281:27653–27661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Calandra T and Roger T: Macrophage
migration inhibitory factor: A regulator of innate immunity. Nat
Rev Immunol. 3:791–800. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitchell R, Bacher M, Bernhagen J,
Pushkarskaya T, Seldin MF and Bucala R: Cloning and
characterization of the gene for mouse macrophage migration
inhibitory factor (MIF). J Immunol. 154:3863–3870. 1995.PubMed/NCBI
|
|
38
|
Merk M, Baugh J, Zierow S, Leng L, Pal U,
Lee SJ, Ebert AD, Mizue Y, Trent JO, Mitchell R, et al: The
Golgi-associated protein p115 mediates the secretion of macrophage
migration inhibitory factor. J Immunol. 182:6896–6906. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Costa-Silva B, Aiello NM, Ocean AJ, Singh
S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, et
al: Pancreatic cancer exosomes initiate pre-metastatic niche
formation in the liver. Nat Cell Biol. 17:816–826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leng L, Metz CN, Fang Y, Xu J, Donnelly S,
Baugh J, Delohery T, Chen Y, Mitchell RA and Bucala R: MIF signal
transduction initiated by binding to CD74. J Exp Med.
197:1467–1476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shi X, Leng L, Wang T, Wang W, Du X, Li J,
McDonald C, Chen Z, Murphy JW, Lolis E, et al: CD44 is the
signaling component of the macrophage migration inhibitory
factor-CD74 receptor complex. Immunity. 25:595–606. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Henne C, Schwenk F, Koch N and Möller P:
Surface expression of the invariant chain (CD74) is independent of
concomitant expression of major histocompatibility complex class II
antigens. Immunology. 84:177–182. 1995.PubMed/NCBI
|
|
43
|
Starlets D, Gore Y, Binsky I, Haran M,
Harpaz N, Shvidel L, Becker-Herman S, Berrebi A and Shachar I:
Cell-surface CD74 initiates a signaling cascade leading to cell
proliferation and survival. Blood. 107:4807–4816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Choi JW, Kim Y, Lee JH and Kim YS: CD74
expression is increased in high-grade, invasive urothelial
carcinoma of the bladder. Int J Urol. 20:251–255. 2013. View Article : Google Scholar
|
|
45
|
Abdul-Aziz AM, Shafat MS, Mehta TK, Di
Palma F, Lawes MJ, Rushworth SA and Bowles KM: MIF-induced stromal
PKCβ/IL8 is essential in human acute myeloid leukemia. Cancer Res.
77:303–311. 2017. View Article : Google Scholar
|
|
46
|
Ponta H, Sherman L and Herrlich PA: CD44:
From adhesion molecules to signalling regulators. Nat Rev Mol Cell
Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoo SA, Leng L, Kim BJ, Du X, Tilstam PV,
Kim KH, Kong JS, Yoon HJ, Liu A, Wang T, et al: MIF
allele-dependent regulation of the MIF coreceptor CD44 and role in
rheumatoid arthritis. Proc Natl Acad Sci USA. 113:E7917–E7926.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mitchell RA, Metz CN, Peng T and Bucala R:
Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic
phospholipase A2 activation by macrophage migration inhibitory
factor (MIF). Regulatory role in cell proliferation and
glucocorticoid action. J Biol Chem. 274:18100–18106. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mitchell RA, Liao H, Chesney J,
Fingerle-Rowson G, Baugh J, David J and Bucala R: Macrophage
migration inhibitory factor (MIF) sustains macrophage
proinflammatory function by inhibiting p53: Regulatory role in the
innate immune response. Proc Natl Acad Sci USA. 99:345–350. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jung H, Seong HA and Ha H: Critical role
of cysteine residue 81 of macrophage migration inhibitory factor
(MIF) in MIF-induced inhibition of p53 activity. J Biol Chem.
283:20383–20396. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jankauskas SS, Wong DWL, Bucala R, Djudjaj
S and Boor P: Evolving complexity of MIF signaling. Cell Signal.
57:76–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hafner A, Bulyk ML, Jambhekar A and Lahav
G: The multiple mechanisms that regulate p53 activity and cell
fate. Nat Rev Mol Cell Biol. 20:199–210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liao H, Bucala R and Mitchell RA:
Adhesion-dependent signaling by macrophage migration inhibitory
factor (MIF). J Biol Chem. 278:76–81. 2003. View Article : Google Scholar
|
|
54
|
Petrenko O and Moll UM: Macrophage
migration inhibitory factor MIF interferes with the Rb-E2F pathway.
Mol Cell. 17:225–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gore Y, Starlets D, Maharshak N,
Becker-Herman S, Kaneyuki U, Leng L, Bucala R and Shachar I:
Macrophage migration inhibitory factor induces B cell survival by
activation of a CD74-CD44 receptor complex. J Biol Chem.
283:2784–2792. 2008. View Article : Google Scholar
|
|
56
|
Bernhagen J, Krohn R, Lue H, Gregory JL,
Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, et
al: MIF is a noncognate ligand of CXC chemokine receptors in
inflammatory and atherogenic cell recruitment. Nat Med. 13:587–596.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schneppenheim J, Dressel R, Hüttl S,
Lüllmann-Rauch R, Engelke M, Dittmann K, Wienands J, Eskelinen EL,
Hermans-Borgmeyer I, Fluhrer R, et al: The intramembrane protease
SPPL2a promotes B cell development and controls endosomal traffic
by cleavage of the invariant chain. J Exp Med. 210:41–58. 2013.
View Article : Google Scholar :
|
|
59
|
Lantner F, Starlets D, Gore Y, Flaishon L,
Yamit-Hezi A, Dikstein R, Leng L, Bucala R, Machluf Y, Oren M and
Shachar I: CD74 induces TAp63 expression leading to B-cell
survival. Blood. 110:4303–4311. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gordin M, Tesio M, Cohen S, Gore Y,
Lantner F, Leng L, Bucala R and Shachar I: c-Met and its ligand
hepatocyte growth factor/scatter factor regulate mature B cell
survival in a pathway induced by CD74. J Immunol. 185:2020–2031.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Assis DN, Leng L, Du X, Zhang CK, Grieb G,
Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, et al: The
role of macrophage migration inhibitory factor in autoimmune liver
disease. Hepatology. 59:580–591. 2014. View Article : Google Scholar
|
|
62
|
Morrison SJ and Scadden DT: The bone
marrow niche for haematopoietic stem cells. Nature. 505:327–334.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wilson A, Laurenti E and Trumpp A:
Balancing dormant and self-renewing hematopoietic stem cells. Curr
Opin Genet Dev. 19:461–468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sugiyama T, Kohara H, Noda M and Nagasawa
T: Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4
chemokine signaling in bone marrow stromal cell niches. Immunity.
25:977–988. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ding L and Morrison SJ: Haematopoietic
stem cells and early lymphoid progenitors occupy distinct bone
marrow niches. Nature. 495:231–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Papayannopoulou T, Craddock C, Nakamoto B,
Priestley GV and Wolf NS: The VLA4/VCAM-1 adhesion pathway defines
contrasting mechanisms of lodgement of transplanted murine
hemopoietic progenitors between bone marrow and spleen. Proc Natl
Acad Sci USA. 92:9647–9651. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cordeiro Gomes A, Hara T, Lim VY,
Herndler-Brandstetter D, Nevius E, Sugiyama T, Tani-Ichi S,
Schlenner S, Richie E, Rodewald HR, et al: Hematopoietic stem cell
niches produce lineage-instructive signals to control multipotent
progenitor differentiation. Immunity. 45:1219–1231. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Koury MJ and Bondurant MC: Erythropoietin
retards DNA breakdown and prevents programmed death in erythroid
progenitor cells. Science. 248:378–381. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sapoznikov A, Pewzner-Jung Y, Kalchenko V,
Krauthgamer R, Shachar I and Jung S: Perivascular clusters of
dendritic cells provide critical survival signals to B cells in
bone marrow niches. Nat Immunol. 9:388–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang GL and Semenza GL: Purification and
characterization of hypoxia-inducible factor 1. J Biol Chem.
270:1230–1237. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Parmar K, Mauch P, Vergilio JA, Sackstein
R and Down JD: Distribution of hematopoietic stem cells in the bone
marrow according to regional hypoxia. Proc Natl Acad Sci USA.
104:5431–5436. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Semenza GL: Oxygen sensing,
hypoxia-inducible factors, and disease pathophysiology. Annu Rev
Pathol. 9:47–71. 2014. View Article : Google Scholar
|
|
73
|
Wellmann S, Guschmann M, Griethe W, Eckert
C, von Stackelberg A, Lottaz C, Moderegger E, Einsiedel HG, Eckardt
KU, Henze G and Seeger K: Activation of the HIF pathway in
childhood ALL, prognostic implications of VEGF. Leukemia.
18:926–933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Frolova O, Samudio I, Benito JM, Jacamo R,
Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, et al:
Regulation of HIF-1α signaling and chemoresistance in acute
lymphocytic leukemia under hypoxic conditions of the bone marrow
microenvironment. Cancer Biol Ther. 13:858–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen H, Shen Y, Gong F, Jiang Y and Zhang
R: HIF-α promotes chronic myelogenous leukemia cell proliferation
by upregulating p21 expression. Cell Biochem Biophys. 72:179–183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kim JW, Tchernyshyov I, Semenza GL and
Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: A metabolic switch required for cellular adaptation to
hypoxia. Cell Metab. 3:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Han ZB, Ren H, Zhao H, Chi Y, Chen K, Zhou
B, Liu YJ, Zhang L, Xu B, Liu B, et al: Hypoxia-inducible factor
(HIF)-1 alpha directly enhances the transcriptional activity of
stem cell factor (SCF) in response to hypoxia and epidermal growth
factor (EGF). Carcinogenesis. 29:1853–1861. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Rey S and Semenza GL: Hypoxia-inducible
factor-1-dependent mechanisms of vascularization and vascular
remodelling. Cardiovasc Res. 86:236–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Magliulo D and Bernardi R: HIF-α factors
as potential therapeutic targets in leukemia. Expert Opin Ther
Targets. 22:917–928. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Falantes JF, Trujillo P, Piruat JI,
Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez
M, González J, Martino ML, et al: Overexpression of GYS1, MIF, and
MYC is associated with adverse outcome and poor response to
azacitidine in myelodysplastic syndromes and acute myeloid
leukemia. Clin Lymphoma Myeloma Leuk. 15:236–244. 2015. View Article : Google Scholar
|
|
81
|
Baugh JA, Gantier M, Li L, Byrne A,
Buckley A and Donnelly SC: Dual regulation of macrophage migration
inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1.
Biochem Biophys Res Commun. 347:895–903. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Oda S, Oda T, Nishi K, Takabuchi S,
Wakamatsu T, Tanaka T, Adachi T, Fukuda K, Semenza GL and Hirota K:
Macrophage migration inhibitory factor activates hypoxia-inducible
factor in a p53-dependent manner. PLoS One. 3:e22152008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gaber T, Schellmann S, Erekul KB, Fangradt
M, Tykwinska K, Hahne M, Maschmeyer P, Wagegg M, Stahn C, Kolar P,
et al: Macrophage migration inhibitory factor counterregulates
dexamethasone-mediated suppression of hypoxia-inducible factor-1
alpha function and differentially influences human CD4+
T cell proliferation under hypoxia. J Immunol. 186:764–774. 2011.
View Article : Google Scholar
|
|
84
|
Schepers K, Pietras EM, Reynaud D, Flach
J, Binnewies M, Garg T, Wagers AJ, Hsiao EC and Passegué E:
Myeloproliferative neoplasia remodels the endosteal bone marrow
niche into a self-reinforcing leukemic niche. Cell Stem Cell.
13:285–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Meisel M, Hinterleitner R, Pacis A, Chen
L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille
N, et al: Microbial signals drive pre-leukaemic myeloproliferation
in a Tet2-deficient host. Nature. 557:580–584. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Richard V, Kindt N and Saussez S:
Macrophage migration inhibitory factor involvement in breast cancer
(review). Int J Oncol. 47:1627–1633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Soumoy L, Kindt N, Ghanem G, Saussez S and
Journe F: Role of macrophage migration inhibitory factor (MIF) in
melanoma. Cancers (Basel). 11:5292019. View Article : Google Scholar
|
|
88
|
Penticuff JC, Woolbright BL, Sielecki TM,
Weir SJ and Taylor JA III: MIF family proteins in genitourinary
cancer: Tumorigenic roles and therapeutic potential. Nat Rev Urol.
16:318–328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhang H, Duan J and Wu O: The expression
of macrophage migration inhibitory factor in the non-small cell
lung cancer. Saudi J Biol Sci. 27:1527–1532. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Binsky I, Haran M, Starlets D, Gore Y,
Lantner F, Harpaz N, Leng L, Goldenberg DM, Shvidel L, Berrebi A,
et al: IL-8 secreted in a macrophage migration-inhibitory factor-
and CD74-dependent manner regulates B cell chronic lymphocytic
leukemia survival. Proc Natl Acad Sci USA. 104:13408–13413. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Cohen S, Shoshana OY, Zelman-Toister E,
Maharshak N, Binsky-Ehrenreich I, Gordin M, Hazan-Halevy I,
Herishanu Y, Shvidel L, Haran M, et al: The cytokine midkine and
its receptor RPTPζ regulate B cell survival in a pathway induced by
CD74. J Immunol. 188:259–269. 2012. View Article : Google Scholar
|
|
92
|
Binsky-Ehrenreich I, Marom A, Sobotta MC,
Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I,
Goldenberg DM, et al: CD84 is a survival receptor for CLL cells.
Oncogene. 33:1006–1016. 2014. View Article : Google Scholar
|
|
93
|
Reinart N, Nguyen PH, Boucas J, Rosen N,
Kvasnicka HM, Heukamp L, Rudolph C, Ristovska V, Velmans T, Mueller
C, et al: Delayed development of chronic lymphocytic leukemia in
the absence of macrophage migration inhibitory factor. Blood.
121:812–821. 2013. View Article : Google Scholar
|
|
94
|
Barthel R, Fedorchenko O, Velmans T, Rosen
N, Nguyen PH, Reinart N, Florin A, Herling M, Hallek M and
Fingerle-Rowson G: CD74 is dispensable for development of chronic
lymphocytic leukemia in Eµ-TCL1 transgenic mice. Leuk Lymphoma.
61:2799–2810. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Binsky I, Lantner F, Grabovsky V, Harpaz
N, Shvidel L, Berrebi A, Goldenberg DM, Leng L, Bucala R, Alon R,
et al: TAp63 regulates VLA-4 expression and chronic lymphocytic
leukemia cell migration to the bone marrow in a CD74-dependent
manner. J Immunol. 184:4761–4769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Islam M, Mohamed EH, Esa E, Kamaluddin NR,
Zain SM, Yusoff YM, Assenov Y, Mohamed Z and Zakaria Z: Circulating
cytokines and small molecules follow distinct expression patterns
in acute myeloid leukaemia. Br J Cancer. 117:1551–1556. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Abdul-Aziz AM, Shafat MS, Sun Y, Marlein
CR, Piddock RE, Robinson SD, Edwards DR, Zhou Z, Collins A, Bowles
KM and Rushworth SA: HIF1α drives chemokine factor pro-tumoral
signaling pathways in acute myeloid leukemia. Oncogene.
37:2676–2686. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Hyrenius-Wittsten A, Pilheden M, Sturesson
H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R,
Garcia-Ruiz C, et al: De novo activating mutations drive clonal
evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
Nat Commun. 9:17702018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Polak R, de Rooij B, Pieters R and den
Boer ML: B-cell precursor acute lymphoblastic leukemia cells use
tunneling nanotubes to orchestrate their microenvironment. Blood.
126:2404–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Daun JM and Cannon JG: Macrophage
migration inhibitory factor antagonizes hydrocortisone-induced
increases in cytosolic IkappaBalpha. Am J Physiol Regul Integr Comp
Physiol. 279:R1043–R1049. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Leng L, Wang W, Roger T, Merk M, Wuttke M,
Calandra T and Bucala R: Glucocorticoid-induced MIF expression by
human CEM T cells. Cytokine. 48:177–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhong XB, Leng L, Beitin A, Chen R,
McDonald C, Hsiao B, Jenison RD, Kang I, Park SH, Lee A, et al:
Simultaneous detection of microsatellite repeats and SNPs in the
macrophage migration inhibitory factor (MIF) gene by thin-film
biosensor chips and application to rural field studies. Nucleic
Acids Res. 33:e1212005. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Baugh JA, Chitnis S, Donnelly SC, Monteiro
J, Lin X, Plant BJ, Wolfe F, Gregersen PK and Bucala R: A
functional promoter polymorphism in the macrophage migration
inhibitory factor (MIF) gene associated with disease severity in
rheumatoid arthritis. Genes Immun. 3:170–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Donn RP, Shelley E, Ollier WE and Thomson
W; British Paediatric Rheumatology Study Group: A novel 5′-flanking
region polymorphism of macrophage migration inhibitory factor is
associated with systemic-onset juvenile idiopathic arthritis.
Arthritis Rheum. 44:1782–1785. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Shi J, Fu H, Jia Z, He K, Fu L and Wang W:
High expression of CPT1A predicts adverse outcomes: A potential
therapeutic target for acute myeloid leukemia. EBioMedicine.
14:55–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sharaf-Eldein M, Elghannam D, Elderiny W
and Abdel-Malak C: Prognostic implication of MIF gene expression in
childhood acute lymphoblastic leukemia. Clin Lab. 64:1429–1437.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Sharaf-Eldein M, Elghannam D and
Abdel-Malak C: MIF-173G/C (rs755622) polymorphism as a risk factor
for acute lymphoblastic leukemia development in children. J Gene
Med. 20:e30442018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Xue Y, Xu H, Rong L, Lu Q, Li J, Tong N,
Wang M, Zhang Z and Fang Y: The MIF -173G/C polymorphism and risk
of childhood acute lymphoblastic leukemia in a Chinese population.
Leuk Res. 34:1282–1286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ramireddy L, Lin CY, Liu SC, Lo WY, Hu RM,
Peng YC and Peng CT: Association study between macrophage migration
inhibitory factor-173 polymorphism and acute myeloid leukemia in
Taiwan. Cell Biochem Biophys. 70:1159–1165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Donnelly SC, Haslett C, Reid PT, Grant IS,
Wallace WA, Metz CN, Bruce LJ and Bucala R: Regulatory role for
macrophage migration inhibitory factor in acute respiratory
distress syndrome. Nat Med. 3:320–323. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Donn RP, Plant D, Jury F, Richards HL,
Worthington J, Ray DW and Griffiths CE: Macrophage migration
inhibitory factor gene polymorphism is associated with psoriasis. J
Invest Dermatol. 123:484–487. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
De la Cruz-Mosso U, Bucala R,
Palafox-Sánchez CA, Parra-Rojas I, Padilla-Gutiérrez JR,
Pereira-Suárez AL, Rangel-Villalobos H, Vázquez-Villamar M,
Angel-Chávez LI and Muñoz-Valle JF: Macrophage migration inhibitory
factor: association of -794 CATT5-8 and -173 G>C polymorphisms
with TNF-α in systemic lupus erythematosus. Hum Immunol.
75:433–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Radstake TR, Sweep FC, Welsing P, Franke
B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R and van Riel
PL: Correlation of rheumatoid arthritis severity with the genetic
functional variants and circulating levels of macrophage migration
inhibitory factor. Arthritis Rheum. 52:3020–3029. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Vivarelli M, D'Urbano LE, Insalaco A, Lunt
M, Jury F, Tozzi AE, Ravelli A, Martini A, Donn R and De Benedetti
F: Macrophage migration inhibitory factor (MIF) and oligoarticular
juvenile idiopathic arthritis (o-JIA): Association of MIF promoter
polymorphisms with response to intra-articular glucocorticoids.
Clin Exp Rheumatol. 25:775–781. 2007.PubMed/NCBI
|
|
116
|
Mousli M, Hopfner R, Abbady AQ, Monté D,
Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a
new family of proteins with an expression that is deregulated in
cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Liu YZ, Jiang YY, Wang BS, Hao JJ, Shang
L, Zhang TT, Cao J, Xu X, Zhan QM and Wang MR: A panel of protein
markers for the early detection of lung cancer with bronchial
brushing specimens. Cancer Cytopathol. 122:833–841. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Fu H, Xing F, Lv Y, Zeng B, You P and Liu
J: ICBP90 mediates Notch signaling to facilitate human
hepatocellular carcinoma growth. Tissue Cell. 54:65–71. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Hopfner R, Mousli M, Jeltsch JM, Voulgaris
A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C: ICBP90, a
novel human CCAAT binding protein, involved in the regulation of
topoisomerase IIalpha expression. Cancer Res. 60:121–128.
2000.PubMed/NCBI
|
|
120
|
Yao J, Leng L, Sauler M, Fu W, Zheng J,
Zhang Y, Du X, Yu X, Lee P and Bucala R: Transcription factor
ICBP90 regulates the MIF promoter and immune susceptibility locus.
J Clin Invest. 126:732–744. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yao J, Luo Y, Zeng C, He H and Zhang X:
UHRF1 regulates the transcriptional repressor HBP1 through MIF in T
acute lymphoblastic leukemia. Oncol Rep. 46:1312021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wolach O and Stone RM: Optimal therapeutic
strategies for mixed phenotype acute leukemia. Curr Opin Hematol.
27:95–102. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Woyach JA, Ruppert AS, Heerema NA,
Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA and Byrd
JC: Chemoimmunotherapy with fludarabine and rituximab produces
extended overall survival and progression-free survival in chronic
lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J
Clin Oncol. 29:1349–1355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cartron G, de Guibert S, Dilhuydy MS,
Morschhauser F, Leblond V, Dupuis J, Mahe B, Bouabdallah R, Lei G,
Wenger M, et al: Obinutuzumab (GA101) in relapsed/refractory
chronic lymphocytic leukemia: Final data from the phase 1/2 GAUGUIN
study. Blood. 124:2196–2202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Byrd JC, Flynn JM, Kipps TJ, Boxer M,
Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J and
Sharman JP: Randomized phase 2 study of obinutuzumab monotherapy in
symptomatic, previously untreated chronic lymphocytic leukemia.
Blood. 127:79–86. 2016. View Article : Google Scholar :
|
|
126
|
Chang BY, Francesco M, De Rooij MF,
Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S,
Pals ST, et al: Egress of CD19(+)CD5(+) cells into peripheral blood
following treatment with the Bruton tyrosine kinase inhibitor
ibrutinib in mantle cell lymphoma patients. Blood. 122:2412–2424.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Souers AJ, Leverson JD, Boghaert ER,
Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH,
Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2
inhibitor, achieves anti-tumor activity while sparing platelets.
Nat Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bilsborrow JB, Doherty E, Tilstam PV and
Bucala R: Macrophage migration inhibitory factor (MIF) as a
therapeutic target for rheumatoid arthritis and systemic lupus
erythematosus. Expert Opin Ther Targets. 23:733–744. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Stein R, Qu Z, Cardillo TM, Chen S,
Rosario A, Horak ID, Hansen HJ and Goldenberg DM: Antiproliferative
activity of a humanized anti-CD74 monoclonal antibody, hLL1, on
B-cell malignancies. Blood. 104:3705–3711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hertlein E, Triantafillou G, Sass EJ,
Hessler JD, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg
DM, Lee RJ and Byrd JC: Milatuzumab immunoliposomes induce cell
death in CLL by promoting accumulation of CD74 on the surface of B
cells. Blood. 116:2554–2558. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Berkova Z, Tao RH and Samaniego F:
Milatuzumab-a promising new immunotherapeutic agent. Expert Opin
Investig Drugs. 19:141–149. 2010. View Article : Google Scholar
|
|
132
|
Martin P, Furman RR, Rutherford S, Ruan J,
Ely S, Greenberg J, Coleman M, Goldsmith SJ and Leonard JP: Phase I
study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in
patients with previously treated B-cell lymphomas. Leuk Lymphoma.
56:3065–3070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Haran M, Mirkin V, Braester A, Harpaz N,
Shevetz O, Shtreiter M, Greenberg S, Mordich O, Amram O,
Binsky-Ehrenreich I, et al: A phase I-II clinical trial of the
anti-CD74 monoclonal antibody milatuzumab in frail patients with
refractory chronic lymphocytic leukaemia: A patient based approach.
Br J Haematol. 182:125–128. 2018. View Article : Google Scholar
|
|
134
|
Kaufman J, Niesvizky R, Stadtmauer EA,
Chanan-Khan A, Siegel D, Horne H, Teoh N, Leoni MJ, Wegener W and
Goldenberg DM: First trial of humanized anti-CD74 monoclonal
antibody (MAb), milatuzumab, in multiple myeloma. Blood.
112:36972008. View Article : Google Scholar
|
|
135
|
Döhner H, Wei AH and Löwenberg B: Towards
precision medicine for AML. Nat Rev Clin Oncol. May 18–2021.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Stahl M and Goldberg AD: Immune checkpoint
inhibitors in acute myeloid leukemia: Novel combinations and
therapeutic targets. Curr Oncol Rep. 21:372019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rashkovan M and Ferrando A: Metabolic
dependencies and vulnerabilities in leukemia. Genes Dev.
33:1460–1474. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Simonetti G, Padella A, do Valle IF,
Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini
M, Ferrari A, et al: Aneuploid acute myeloid leukemia exhibits a
signature of genomic alterations in the cell cycle and protein
degradation machinery. Cancer. 125:712–725. 2019. View Article : Google Scholar
|
|
139
|
Alhosin M, Razvi SSI, Sheikh RA, Khan JA,
Zamzami MA and Choudhry H: Thymoquinone and difluoromethylornithine
(DFMO) synergistically induce apoptosis of human acute T
lymphoblastic leukemia jurkat cells through the modulation of
epigenetic pathways. Technol Cancer Res Treat.
19:15330338209474892020. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Guan D, Factor D, Liu Y, Wang Z and Kao
HY: The epigenetic regulator UHRF1 promotes ubiquitination-mediated
degradation of the tumor-suppressor protein promyelocytic leukemia
protein. Oncogene. 32:3819–3828. 2013. View Article : Google Scholar :
|
|
141
|
Chow M, Gao L, MacManiman JD, Bicocca VT,
Chang BH, Alumkal JJ and Tyner JW: Maintenance and pharmacologic
targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
Oncogene. 37:5221–5232. 2018. View Article : Google Scholar : PubMed/NCBI
|
